# Camrelizumab Combined With Apatinib for Advanced Gastric or Esophagogastric Adenocarcinoma

> **NCT04948125** · PHASE2 · UNKNOWN · sponsor: **Henan Cancer Hospital** · enrollment: 20 (estimated)

## Conditions studied

- Advanced Gastric Carcinoma

## Interventions

- **DRUG:** camrelizumab
- **DRUG:** Apatinib Mesylate

## Key facts

- **NCT ID:** NCT04948125
- **Lead sponsor:** Henan Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-04-28
- **Primary completion:** 2022-06-03
- **Final completion:** 2023-08-03
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2021-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04948125

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04948125, "Camrelizumab Combined With Apatinib for Advanced Gastric or Esophagogastric Adenocarcinoma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04948125. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*